Australia's Radiopharm Theranostics rises after first patient dosed in lung cancer trial

Radiopharm Theranostics

10/07/2024 03:10

** Shares of Radiopharm Theranostics  RAD.AX  rise as much
as 5.7% to A$0.037
    ** Stock set for best day since June 26
    ** Pharmaceutical co doses first patient in Phase-1 clinical
trial of RAD 204, which is being developed to cure non-small
cell lung cancer
    ** Stock has fallen 52.7% this year, as of last close

 (Reporting by Shivangi Lahiri in Bengaluru)
 ((shivangi.lahiri@thomsonreuters.com))